Expertise in
56
conditions

Dr. Perminder J. Bhatia

Neurology
Neuro Pain Medical Center - Perminder Bhatia
736 E Bullard Ave Ste 101, 
Fresno, CA 
Offers Telehealth
Expertise in
56
conditions
Neuro Pain Medical Center - Perminder Bhatia
736 E Bullard Ave Ste 101, 
Fresno, CA 

Overview

Perminder Bhatia is a Neurologist practicing medicine in Fresno, California.

Dr. Bhatia is highly rated in 56 conditions, according to our data. His clinical expertise encompasses Seizures, Autosomal Dominant Partial Epilepsy with Auditory Features, Memory Loss, and Serotonin Syndrome.

He is actively involved in clinical research, co-authoring 6 peer reviewed articles and participating in 13 clinical trials.

Specialties

Neurology

Licenses

Psychiatry & Neurology in CA

Hospital Affiliations

Community Regional Medical Center
Saint Agnes Medical Center
Clovis Community Medical Center
Adventist Health Hanford
Kaweah Health Medical Center

Languages Spoken

English
Punjabi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Neuro Pain Medical Center - Perminder Bhatia
736 E Bullard Ave Ste 101, Fresno, CA 93710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: June 12, 2026
Intervention Type: Drug
Study Drug: LY3372689
Study Phase: Phase 2
Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study
Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study
Enrollment Status: Completed
Publish Date: April 13, 2026
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Enrollment Status: Completed
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drug: YKP3089
Study Phase: Phase 3
A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.
A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.
Enrollment Status: Withdrawn
Publish Date: March 01, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 1
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia
A Phase 2, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia
Enrollment Status: Completed
Publish Date: February 14, 2024
Intervention Type: Drug
Study Drug: ABP-450
Study Phase: Phase 2
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: BIIB092
Study Phase: Phase 2
View 9 Less Clinical Trials

6 Total Publications

Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial.
Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial.
Journal: The Lancet. Neurology
Published: November 06, 2025
Similar Doctors
Expertise in
10
conditions
Dr. Madhav Suri
Neurology
Expertise in
10
conditions
Dr. Madhav Suri
Neurology
Referral may be required

Office

7151 N Cedar Ave Ste 102, 
Fresno, CA 
 (2.8 miles away)
559-322-7766
Languages Spoken:
English, Hindi
See accepted insurances

Madhav Suri is a Neurologist practicing medicine in Fresno, California. Dr. Suri is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Autosomal Dominant Partial Epilepsy with Auditory Features, Memory Loss, Seizures, and Progressive Myoclonic Epilepsy.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Community Cancer Institute

785 N Medical Center Dr W, 
Clovis, CA 
 (4.4 miles away)
559-387-1616
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Turner is a Neurologist practicing medicine in Clovis, California. Dr. Turner is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Meningioma, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), and Glioma.

Expertise in
8
conditions
Expertise in
8
conditions
Referral may be required
2335 E Kashian Ln, Suite 301, 
Fresno, CA 
 (5.6 miles away)
559-264-9100
Languages Spoken:
English

Ernestina Saxton is a Neurologist practicing medicine in Fresno, California. Dr. Saxton is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Thoracic Outlet Syndrome, Syringomyelia, Chiari Malformation Type 2, and Arachnoid Cysts.

Frequently Asked Questions about Dr. Perminder J. Bhatia

How do I make an appointment with Dr. Perminder J. Bhatia?

You can book an appointment with Dr. Perminder J. Bhatia by calling their office at 661-432-2456. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Perminder J. Bhatia a top-rated expert for Seizures?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Perminder J. Bhatia is classified as an Distinguished expert for Seizures, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Perminder J. Bhatia specialize in?

While Dr. Perminder J. Bhatia is a Neurology, they have specific expertise in Seizures, Autosomal Dominant Partial Epilepsy with Auditory Features, and Memory Loss. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Perminder J. Bhatia participate in research or clinical trials?

Yes. Dr. Perminder J. Bhatia has published 6 articles and abstracts on conditions like Seizures. You can view a list of Dr. Perminder J. Bhatia's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Perminder J. Bhatia accept my insurance?

Dr. Perminder J. Bhatia accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 661-432-2456 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bhatia's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 45 Advanced Conditions
    View All 95 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile